These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37781182)

  • 1. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma.
    Li X; Li G; Chen D; Su L; Wang RP; Zhou Y
    Front Oncol; 2023; 13():912168. PubMed ID: 37781182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.
    Wu JY; Kang K; Yi J; Yang B
    World J Clin Cases; 2022 Jun; 10(18):6110-6118. PubMed ID: 35949835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
    Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
    J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
    Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
    J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
    Li G; Gong S; Wang N; Yao X
    Front Immunol; 2022; 13():989966. PubMed ID: 36090976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
    Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
    Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
    Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
    Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma.
    Chirasuthat P; Chayavichitsilp P
    Case Rep Dermatol; 2018; 10(2):198-202. PubMed ID: 30186133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.
    Cao J; Li Q; Zhi X; Yang F; Zhu W; Zhou T; Hou X; Chen D
    Transl Cancer Res; 2021 Aug; 10(8):3870-3876. PubMed ID: 35116686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer.
    Riano I; Cristancho C; Treadwell T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620914796. PubMed ID: 32207346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.
    Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z
    Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
    Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
    Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.
    Arora R; Pande RK; Panwar S; Gupta V
    Indian J Crit Care Med; 2021 May; 25(5):575-579. PubMed ID: 34177178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung.
    Otsuka T; Tanaka A; Azukizawa H; Sasaki S; Ishijima M; Matsuki T; Osa A; Nakatani T; Kuroyama M; Hirata H; Kijima T
    Int Cancer Conf J; 2017 Jan; 6(1):38-41. PubMed ID: 31149467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carbamazepine induced Stevens-Johnson syndrome in Han Chinese with positive
    Xu YY; Sun ZL; Zhang XL; Liu ZL; Liu W; Guan X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):755-757. PubMed ID: 37534663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.